AXIOS November 6, 2025
Medicare will cover weight-loss drugs under a deal between the Trump administration and drugmakers Eli Lilly and Novo Nordisk to cut prices for blockbuster diabetes and anti-obesity drugs.
Why it matters: About 10% of Medicare enrollees will be newly eligible for coverage of GLP-1 drugs because of the deal, a senior administration official told reporters Thursday.
- The announcement could make it easier for seniors to use popular drugs like Novo Nordisk’s Ozempic and Wegovy and Eli Lilly’s Zepbound.
- It also lowers the price of the drugs for state Medicaid programs, which could increase coverage for lower-income Americans.
- The expanded Medicare coverage will be available through a pilot program, according to a statement from Novo Nordisk.
The big...
Today's Sponsors
Today's Sponsor